Get the Stockscreener App
17.60
2.98%
0.51
After Hours:
17.60
Legend Biotech Corp Adr stock is traded at $17.60, with a volume of 1.12M.
It is up +2.98% in the last 24 hours and down -10.75% over the past month.
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
See More
Previous Close:
$17.09
Open:
$17.26
24h Volume:
1.12M
Relative Volume:
0.50
Market Cap:
$3.26B
Revenue:
$1.03B
Net Income/Loss:
$-297.43M
P/E Ratio:
-10.90
EPS:
-1.615
Net Cash Flow:
$-261.39M
1W Performance:
-3.35%
1M Performance:
-10.75%
6M Performance:
-46.37%
1Y Performance:
-49.79%
1-Day Range:
$17.26
$17.82
1-Week Range:
$16.96
$18.80
52-Week Range:
$16.24
$44.90
Legend Biotech Corp Adr Stock (LEGN) Company Profile
Name
Legend Biotech Corp Adr
Sector
Industry
Phone
-
Address
-
Compare LEGN vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LEGN
Legend Biotech Corp Adr
|
17.60 | 3.16B | 1.03B | -297.43M | -261.39M | -1.615 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Legend Biotech Corp Adr Stock (LEGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-12-26 | Downgrade | Rothschild & Co Redburn | Buy → Neutral |
| Jan-22-26 | Downgrade | TD Cowen | Buy → Hold |
| Jan-07-26 | Initiated | Oppenheimer | Outperform |
| Oct-07-25 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-08-24 | Initiated | Redburn Atlantic | Buy |
| Jun-17-24 | Initiated | Truist | Buy |
| May-24-24 | Reiterated | H.C. Wainwright | Buy |
| May-23-24 | Initiated | Deutsche Bank | Buy |
| Apr-17-24 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Apr-03-24 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-13-24 | Initiated | Raymond James | Outperform |
| Dec-19-23 | Initiated | Scotiabank | Sector Perform |
| Nov-06-23 | Initiated | Goldman | Buy |
| May-25-23 | Initiated | William Blair | Mkt Perform |
| May-22-23 | Initiated | Daiwa Securities | Buy |
| Mar-29-23 | Initiated | H.C. Wainwright | Buy |
| Mar-24-23 | Initiated | RBC Capital Mkts | Outperform |
| Dec-06-22 | Initiated | UBS | Buy |
| Nov-02-22 | Initiated | Evercore ISI | Outperform |
| Nov-01-22 | Initiated | Cowen | Outperform |
| Oct-31-22 | Initiated | Guggenheim | Neutral |
| Jun-17-22 | Initiated | BMO Capital Markets | Outperform |
| Mar-15-22 | Initiated | Barclays | Overweight |
| Jan-31-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-06-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-21-21 | Initiated | Piper Sandler | Overweight |
| May-18-21 | Initiated | BTIG Research | Buy |
| Jul-01-20 | Initiated | JP Morgan | Overweight |
| Jul-01-20 | Initiated | Jefferies | Buy |
| Jun-30-20 | Initiated | Morgan Stanley | Overweight |
View All
Legend Biotech Corp Adr Stock (LEGN) Latest News
Hudson Bay Capital Management LP Has $7.17 Million Stock Position in Legend Biotech Corporation Sponsored ADR $LEGN - MarketBeat
Legend Biotech Q1 EPS Estimate Decreased by HC Wainwright - MarketBeat
Q2 EPS Estimates for Legend Biotech Lowered by HC Wainwright - MarketBeat
Braidwell LP Decreases Position in Legend Biotech Corporation Sponsored ADR $LEGN - MarketBeat
ArrowMark Colorado Holdings LLC Cuts Position in Axis Capital Holdings Limited $AXS - Defense World
UiPath (NYSE:PATH) Price Target Cut to $13.00 by Analysts at Wells Fargo & Company - Defense World
Capital International Investors Sells 140,873 Shares of Legend Biotech Corporation Sponsored ADR $LEGN - MarketBeat
916,443 Shares in Bath & Body Works, Inc. $BBWI Bought by Capital International Investors - Defense World
CLEAR Secure, Inc. (NYSE:YOU) Receives Average Recommendation of “Hold” from Analysts - Defense World
Royal Bank Of Canada Lowers Legend Biotech (NASDAQ:LEGN) Price Target to $62.00 - Defense World
Legend Biotech Plans to List in HK as Early as This Yr, Raising at Least US$300M: Wire - AASTOCKS.com
RBC Capital lowers Legend Biotech stock price target on model updates By Investing.com - Investing.com South Africa
RBC Capital lowers Legend Biotech stock price target on model updates - Investing.com India
Legend Biotech Q4 2025 slides: CARVYKTI turns profitable, $555M sales By Investing.com - Investing.com South Africa
Raymond James reiterates Legend Biotech stock rating on strong Q4 results - Investing.com India
Truist reiterates Buy on Legend Biotech stock, $70 target on capacity - Investing.com
Jefferies reiterates Legend Biotech stock rating on Carvykti sales - Investing.com India
Jefferies reiterates Legend Biotech stock rating on Carvykti sales By Investing.com - Investing.com South Africa
Legend Biotech Q4 Earnings Call Highlights - Yahoo Finance
Legend Biotech Q4 2025 slides: CARVYKTI turns profitable, $555M sales - Investing.com India
Earnings call transcript: Legend Biotech Q4 2025 shows strong growth - Investing.com
Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Legend Biotech earnings on deck as profitability looms - Investing.com South Africa
Triata Capital Ltd Purchases 54,300 Shares of Legend Biotech Corporation Sponsored ADR $LEGN - MarketBeat
Raymond James reiterates Legend Biotech stock rating after rival approval - Investing.com South Africa
Legend Biotech (NASDAQ:LEGN) Trading Up 5.5%Here's Why - MarketBeat
Artisan Partners Limited Partnership Purchases 425,684 Shares of Legend Biotech Corporation Sponsored ADR $LEGN - MarketBeat
Westfield Capital Management Co. LP Lowers Stock Position in Legend Biotech Corporation Sponsored ADR $LEGN - MarketBeat
Nuclear Stocks To Research – February 23rd - Defense World
Raymond James reiterates Legend Biotech stock rating on valuation gap - Investing.com South Africa
Etsy (NYSE:ETSY) Stock Price Up 6.6% on Earnings Beat - Defense World
Barclays Cite Favorable Long-Term Outlook For Legend Biotech Corporation (LEGN) Despite Near-Term Expectation Revisions - Finviz
FDA Guidance on MRD Negativity Bodes Well for Legend Biotech (LEGN) - Finviz
Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Legend Biotech (NASDAQ:LEGN) Downgraded by Rothschild & Co Redburn to “Neutral” - Defense World
Legend Biotech stock rating downgraded by Rothschild Redburn on competition concerns By Investing.com - Investing.com India
Legend Biotech stock rating downgraded by Rothschild Redburn on competition concerns - Investing.com
Legend Biotech (NASDAQ:LEGN) Makes Strides in Nasdaq Composite Biotech Field - Kalkine Media
Investment Analysts’ Weekly Ratings Updates for Legend Biotech (LEGN) - Defense World
Legend Biotech (LEGN) Shakes Up Board - Finviz
Legend Biotech (NASDAQ:LEGN) Sets New 12-Month LowTime to Sell? - MarketBeat
H.C. Wainwright Highlight Curative Potential of Legend Biotech Corporation (LEGN)'s Carvykti Despite Sales Miss - Finviz
82,516 Shares in Legend Biotech Corporation Sponsored ADR $LEGN Bought by Mutual of America Capital Management LLC - MarketBeat
Legend Biotech stock hits 52-week low at $18.07 By Investing.com - Investing.com South Africa
Legend Biotech stock hits 52-week low at $18.07 - Investing.com
Legend Biotech (NASDAQ:LEGN) Hits New 12-Month LowTime to Sell? - MarketBeat
Legend Biotech (LEGN) Advances Cell Therapy Innovation and Expands Oncology Pipeline - Finviz
Legend Biotech FY2025 EPS Estimate Lifted by HC Wainwright - MarketBeat
Legend Biotech (NASDAQ:LEGN) Price Target Lowered to $50.00 at HC Wainwright - Defense World
Legend Biotech Corp Adr Stock (LEGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):